Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, CA, USA.
Moores Cancer Center at UC San Diego Health, La Jolla, CA, USA.
J Natl Cancer Inst Monogr. 2024 Aug 15;2024(66):282-289. doi: 10.1093/jncimonographs/lgad028.
The benefits of cannabis in symptom management among cancer survivors are widely acknowledged; however, patterns of cannabis use by cancer stage at diagnosis are unknown.
Here, we examined the association between cancer stage at diagnosis and consideration of cannabis use since diagnosis. We analyzed cross-sectional survey data from 954 cancer survivors, weighted to be representative of a National Cancer Institute-Designated Comprehensive Cancer Center's patient population. We used survey-weighted multivariable logistic regression to examine the association between cancer stage at diagnosis (advanced [III/IV] versus non-advanced [I/II]) and consideration of cannabis use (yes versus no) since diagnosis.
Sixty percent of the population was diagnosed with non-advanced stages of cancer, and 42% had considered using cannabis since diagnosis. The odds of consideration of cannabis use were 63% higher (odds ratio = 1.63, 95% confidence interval = 1.06 to 2.49) among cancer survivors diagnosed at stages III/IV than among those diagnosed at stages I/II.
Cancer stage may be a predictor of consideration of cannabis use after diagnosis.
人们普遍承认大麻在癌症幸存者的症状管理中的益处；然而，尚不清楚诊断时癌症分期与使用大麻的模式之间的关系。
在这里，我们研究了诊断时癌症分期与自诊断以来考虑使用大麻之间的关联。我们分析了来自 954 名癌症幸存者的横断面调查数据，这些数据经过加权处理，以代表国立癌症研究所指定的综合癌症中心的患者人群。我们使用调查加权多变量逻辑回归来检查诊断时癌症分期（晚期 [III/IV] 与非晚期 [I/II]）与自诊断以来考虑使用大麻（是与否）之间的关联。
该人群中有 60%被诊断为非晚期癌症，42%自诊断以来考虑使用大麻。与诊断为 I/II 期的患者相比，诊断为 III/IV 期的癌症幸存者考虑使用大麻的可能性高 63%（优势比=1.63，95%置信区间=1.06 至 2.49）。
癌症分期可能是诊断后考虑使用大麻的预测因素。
